Hepatic safety profile of elvitegravir/cobicistat/emtricitabine/tenofovir DF in HIV/HCV co-infected subjects in the STRATEGY switch trials

被引：0
|
作者：
Rashbaum, B. [1 ]
Lucasti, C. [2 ]
Mounzer, K. [3 ]
Melbourne, K. [4 ]
Kwon, P. [4 ]
Piontkowsky, D. [4 ]
机构：
[1] Capital Med Associates PC, Washington, DC USA
[2] South Jersey Infect Dis, Somers Point, NJ USA
[3] Philadelphia FIGHT, Philadelphia, PA USA
[4] Gilead Sci Inc, Foster City, CA 94404 USA
来源：
ANTIVIRAL THERAPY | 2014年 / 19卷
关键词：
D O I：
暂无
中图分类号：
R51 [传染病];
学科分类号：
100401 ;
摘要：
P25
引用
收藏
页码：A44 / A45
页数：2
相关论文
共 50 条
  • [31] EFFECTIVENESS, SAFETY AND TOLAREBILITY PROFILE OF STRIBILD® (ELVITEGRAVIR/COBICISTAT/EMITRICITABINE/TENOFOVIR DISOPROXIL FUMARATE) IN HIV-1-INFECTED PATIENTS IN THE CLINICAL SETTING
    Heiko, J.
    Laura, T.
    Slobodan, R.
    SEXUALLY TRANSMITTED INFECTIONS, 2015, 91 : A236 - A237
  • [32] Switching to the single-tablet regimen of elvitegravir, cobicistat, emtricitabine, and tenofovir DF from non-nucleoside reverse transcriptase inhibitor plus coformulated emtricitabine and tenofovir DF regimens: Week 96 results of STRATEGY-NNRTI
    Pozniak, Anton
    Flamm, Jason
    Antinori, Andrea
    Bloch, Mark
    Ward, Douglas
    Berenguer, Juan
    Cote, Pierre
    Andreatta, Kristen
    Garner, William
    Szwarcberg, Javier
    Nguyen-Cleary, Thai
    McColl, Damian J.
    Piontkowsky, David
    HIV CLINICAL TRIALS, 2017, 18 (04): : 141 - 148
  • [33] SAFETY AND EFFICACY OF ELVITEGRAVIR/COBICISTAT/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE IN TREATMENT-NAIVE JAPANESE PATIENTS WITH HIV-1 INFECTION
    Yajima, K.
    Yagura, H.
    Yukawa, S.
    Hirota, K.
    Ikuma, M.
    Kasai, D.
    Watanabe, D.
    Nishida, Y.
    Uehira, T.
    Shirasaka, T.
    SEXUALLY TRANSMITTED INFECTIONS, 2015, 91 : A237 - A237
  • [34] Safety and efficacy of switching to elvitegravir, cobicistat, emtricitabine, tenofovir disoproxil fumarate in treatment-experienced people with HIV: a multicenter cohort study
    De Castro, Nathalie
    Brun, Alexandre
    Sellier, Pierre
    Hamet, Gwenn
    Mechai, Frederic
    Garrait, Valerie
    Chabrol, Amelie
    Bouldouyre, Marie-Anne
    Froguel, Eric
    Troisvallets, Didier
    Caraux-Paz, Pauline
    Delaugerre, Constance
    Rozenbaum, Willy
    Molina, Jean-Michel
    AIDS RESEARCH AND THERAPY, 2023, 20 (01)
  • [35] Safety and efficacy of switching to elvitegravir, cobicistat, emtricitabine, tenofovir disoproxil fumarate in treatment-experienced people with HIV: a multicenter cohort study
    Nathalie De Castro
    Alexandre Brun
    Pierre Sellier
    Gwenn Hamet
    Frédéric Mechaï
    Valérie Garrait
    Amélie Chabrol
    Marie-Anne Bouldouyre
    Eric Froguel
    Didier Troisvallets
    Pauline Caraux-Paz
    Constance Delaugerre
    Willy Rozenbaum
    Jean-Michel Molina
    AIDS Research and Therapy, 20
  • [36] Ninety-six-week efficacy and safety of elvitegravir/cobicistat/emtricitabine/tenofovir DF - subgroup analyses by baseline HIV-1 RNA and CD4 cells.
    Zolopa, Andrew
    Rockstroh, Jurgen
    Orkin, Chloe
    Stellbrink, Hans-Jurgen
    Walmsley, Sharon
    Cooper, David
    Zhong, Lijie
    Fordyce, Marshall
    Rhee, Martin
    Bernstein, Mark
    Hindman, Jason T.
    Szwarcberg, Javier
    PHARMACOTHERAPY, 2013, 33 (10): : E210 - E211
  • [37] Safety and Tolerability of Co-formulated Tenofovir/Emtricitabine/Elvitegravir/Cobicistat ("Quad") for Non-occupational Post-exposure Prophylaxis
    Mayer, Kenneth H.
    Gregor, Charles
    Gelman, Marcy
    Grasso, Chris
    Melbourne, Kathy
    Mimiaga, Matthew J.
    AIDS RESEARCH AND HUMAN RETROVIRUSES, 2014, 30 : A155 - A155
  • [38] Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate in Asian Subjects with Human Immunodeficiency Virus 1 Infection: A Sub-Analysis of Phase 3 Clinical Trials
    Choi, Jun Yong
    Sungkanuparph, Somnuek
    Anekthananon, Thanomsak
    Sax, Paul
    DeJesus, Edwin
    Edelstein, Howard
    Nelson, Mark
    DeMorin, Jennifer
    Liu, Hui C.
    Swamy, Raji
    Bahn, Joonwoo
    Hwang, SunJin
    Yang, Sang Youn
    Ng, Christopher
    Piontkowsky, David
    INFECTION AND CHEMOTHERAPY, 2016, 48 (03): : 219 - 224
  • [39] Hepatic fibrosis and immune phenotype vary by HCV viremia in HCV/HIV co-infected subjects A Women's interagency HIV study
    Desai, Seema N.
    Dodge, Jennifer L.
    Landay, Alan L.
    Glesby, Marshall J.
    Latham, Patricia S.
    Villacres, Maria C.
    French, Audrey L.
    Gange, Stephen J.
    Greenblatt, Ruth M.
    Peters, Marion G.
    MEDICINE, 2016, 95 (33)
  • [40] Simplification to single-tablet regimen of elvitegravir, cobicistat, emtricitabine, tenofovir DF from multi-tablet ritonavir-boosted protease inhibitor plus coformulated emtricitabine and tenofovir DF regimens: week 96 results of STRATEGY-PI
    Arribas, Jose R.
    DeJesus, Edwin
    van Lunzen, Jan
    Zurawski, Christine
    Doroana, Manuela
    Towner, William
    Lazzarin, Adriano
    Nelson, Mark
    McColl, Damian
    Andreatta, Kristen
    Swamy, Raji
    Szwarcberg, Javier
    Thai Nguyen
    HIV CLINICAL TRIALS, 2017, 18 (03): : 118 - 125
12345